DCAT Week 2025
Join us to discuss how we can solve your API challenges
Meet us at Suite #1123, #1125 and #1126
March 17 - 20, 2025
LOTTE New York Palace Hotel, 455 Madison Avenue, New York, NY 10022 (Madison at 50th Street)Our Team at DCAT Week 2025
Deepak Sapra
CEO, Pharmaceutical Services & Active Ingredients
Kalpesh Modi
Vice President, and Head – EU Market, API & B2B Collaborations
Dr. NM Sekhar
Vice President, API R&D
E Sreedhar
Executive Vice President, API Regulatory Affairs
Juli Asmonga
Associate Vice President, API Sales & Marketing - North America
Lalitha Kumari
Head API Product Management and Regional Sales Lead - US & Canada
Dileep Kumar K
Director, API Sales & Marketing - North America
About Dr.Reddy’s API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 250+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
-
250+ APIs
-
8 Manufacturing sites
-
1900 drug master files across global markets.
-
Over 170 ANDAs and 500 DMFs
-
More than 1000 patents field, and more than 70 own patents granted
-
Experience with complex APIs and formulations supporting early market entries.
-
Preferred pharma API supplier for pharma companies in more than 80 countries.
Sustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
What we achieved in the past year:
Our Achievement (awards)
25/04/2024
USP recognized Dr. Reddy’s with a crystal award for significant contribution towards “New and modernized monograph submissions”
05/04/2024
Dr. Reddys Strategic collaboration with Industrial Promotion Services (IPS) to support the East African Combined Pharmaceutical Center (EACPC) in Kenya
05/12/2023
Dr. Reddy's Pioneers Pharma Advancements Through Strategic Partnerships and Innovation: A Glimpse into Vision 2030: Growth Trajectory and Opportunities for Indian Pharma
15/02/2023
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row
15/02/2023
S&P Global’s Sustainability Yearbook for the 3rd year
04/11/2022
Dr. Reddy’s API received the excellence in API – Technical Documentation award at Aché Laboratórios Parcerias para a Excelência (Partnerships – Excellence) event!
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
11/11/2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
19/10/2020
Dr. Reddy's recognized at the CPhI Pharma Awards 2020 as the winner in the category of ‘Excellence in Pharma: Sustainability’
03/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2020
05/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2019
Our Plants
About DCAT Week 2025
DCAT Week, hosted annually in New York City by the Drug, Chemical & Associated Technologies Association (DCAT), is the premier gathering for companies engaged in the global bio/pharmaceutical manufacturing value chain. It brings together over 10,000 industry professionals from across the world to foster collaboration, drive strategic business development, and shape the future of the bio/pharmaceutical industry.
DCAT is a not-for-profit, volunteer-led organization committed to the growth and advancement of its global membership. Joining DCAT and participating in DCAT Week isn’t just an event—it’s an investment in your company’s future within this dynamic and evolving industry. DCAT Week attracts key decision-makers from across the bio/pharmaceutical value chain, including professionals in sourcing, procurement, business development, corporate support, and licensing. The event serves as a hub for leaders looking to strengthen relationships, explore new business opportunities, showcase capabilities, and drive strategic objectives.
免責事項
このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。
Let’s talk API sourcing live at
Tackle sourcing bottlenecks and compliance hurdles